FOURTH QUARTER February 1 – April 30, 2014
- Consolidated Net sales amounted to € 2 thousand (-) [1]
- Operating income amounted to € -3,886 thousand (-2,417)
- Net income after tax amounted to € -4,168 thousand (-2,531)
- Earnings per share amounted to € -0.05 (-0.03)
- Comprehensive income amounted to € -4,168 thousand (-2,531)
- Conditional FDA approval for Paccal® Vet
- MSEK 72 private placement completed
- MSEK 40 bank loan received
THE FISCAL YEAR May 1, 2013 – April 30, 2014
- Consolidated Net sales amounted to € 7 thousand (-)
- Operating income amounted to € -10,818 thousand (-7,453)
- Net income after tax amounted to € -11,592 thousand (-7,983)
- Earnings per share amounted to € -0.14 (-0.12)
- Comprehensive income amounted to € -11,592 thousand (-7,983)
- Increased funding of loans
- FDA approved Oasmia’s production facility
- Oasmia initiated a clinical program for treatment of breast cancer with Paclical®
- Oasmia initiated pre-clinical studies with OAS-19, which is the first pharmaceutical project with a combination of two active cytostatics in one infusion.
- The Board does not propose a dividend for the past fiscal year
EVENTS AFTER THE CLOSING DAY
- The Swedish Medical Products Agency approved Oasmia’s production facility
- First shipment of Paccal Vet-CA1 to Abbott Animal Health was accomplished
- Paccal Vet-CA1 and XR-17 is presented at ACVIM Forum in Nashville